Z

Zealand University Hospital, Roskilde | Clinical Research Unit

Research site

(Unclaimed)

Location

Vestermarksvej 9, 3. sal., Roskilde, Sjælland, Denmark

Site insights

Top conditions

Top treatments

Cyclophosphamide

Obinutuzumab

Capecitabine

R-CHOP

Prednisone

Doxorubicin Hydrochloride

Mitomycin c

Vincristine

Ensifentrine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 10 total trials

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Active, not recruiting

Diffuse Large B-Cell Lymphoma

Drug: Epcoritamab

Drug: Cyclophosphamide

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed a...

Enrolling

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Rituximab

Drug: Sonrotoclax

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer (COBRA-NMIBC)

The investigartors will conduct a randomized, multinational study with the aim to assess if the efficacy of a dose dense chemoablation with Mitomycin...

Enrolling

Non-Muscle Invasive Bladder Cancer

Drug: Mitomycin c